scholarly journals Systemic antibiotic therapy of patients with acute bacterial sinusitis taking into account resistance

2021 ◽  
pp. 172-177
Author(s):  
S. V. Starostina ◽  
D. A. Sivokhin
Keyword(s):  
Antibiotic Therapy ◽  
Severe Disease ◽  
Viral Disease ◽  
Systemic Antibiotic ◽  
Systemic Antibiotic Therapy ◽  
Causative Agents ◽  
Intracranial Complications ◽  
Acute Bacterial Rhinosinusitis ◽  
Third Line ◽  
The Right

Acute rhinosinusitis is one of the most common diseases in the world. According to statistics, about 10 million cases are registered in Russia every year.Acute bacterial rhinosinusitis (ABRS) in most cases develops as a result of an acute respiratory viral disease, proceeds easily and it does not require antibiotic therapy. However, it significantly reduces the patient's quality of life in cases of moderate and severe disease, and in the absence of timely treatment, can lead to intracranial complications (meningitis, encephalitis, intracranial abscesses, etc.) and orbital (reactive edema of the eyelid, phlegmon of the orbit, periorbital abscesses, etc.). To avoid complications, with exacerbation of rhinosinusitis, it is necessary to choose the right antibiotic therapy, taking into account the resistance of the microorganisms that caused the disease.The article describes the differential diagnosticprinciples of bacterial rhinosinusitis according to the latest recommendations and research in this area, the most common antibiotic-resistant pathogens in the practice of an ENT doctor are presented, the issue of choosing the correct systemic antibiotic therapy for the treatment of patients with moderate and severe acute bacterial rhinosinusitis is considered according to modern data on the sensitivity of bacterial pathogens to antibacterial drugs prescribed in the otorhinolaryngologist's practice. The article presents data on a new universal cephalosporin of the 3rd generation (the active ingredient is cefditoren), as a second- and third-line drug, due to its high activity against most causative agents of acute bacterial rhinosinusitis, and clinical observation using the above antibacterial agent within the framework of the considered topics.

scholarly journals Chemo-Therapeutic Management of An Acute Abscess in a Male Asian Elephant (Elephas maximus)

2020 ◽  
pp. 326-330
Author(s):  
Anitta PL ◽  
Girish U ◽  
Chris Seymour
Keyword(s):  
Antibiotic Therapy ◽  
Asian Elephant ◽  
Elephas Maximus ◽  
Therapeutic Management ◽  
Uneventful Recovery ◽  
Systemic Antibiotic ◽  
Systemic Antibiotic Therapy ◽  
Pelvic Limb ◽  
Topical Treatments ◽  
The Right

A 40-year-old male Asian elephant was presented to the Veterinary Polyclinic, North Paravur with right pelvic limb lameness and a swelling in the right ilial region, which had developed after darting one month previously. The swelling was diagnosed as a unilateral acute abscess, which was lanced, drained and lavaged. Topical treatments, systemic antibiotic therapy and an analgesic were administered, and the animal made an uneventful recovery.

Delayed tooth replantation in rats: effect of systemic antibiotic therapy with amoxicillin and tetracycline

2015 ◽  
Vol 31 (6) ◽  
pp. 448-456 ◽  
Author(s):  
Weglis Dyanne de Souza Gomes ◽  
Cristina Antoniali Silva ◽  
Moriel Evangelista Melo ◽  
Vanessa Ferreira da Silva ◽  
Melyna Marques de Almeida ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Systemic Antibiotic ◽  
Tooth Replantation ◽  
Systemic Antibiotic Therapy

Systemic antibiotic therapy in periodontics

1996 ◽  
Vol 10 (1) ◽  
pp. 45-78 ◽  
Author(s):  
Arie Jan Van Winkelhoff ◽  
Thomas E. Rams ◽  
Jørgen Slots
Keyword(s):  
Antibiotic Therapy ◽  
Systemic Antibiotic ◽  
Systemic Antibiotic Therapy

Timing Affects the Clinical Outcome of Adjunctive Systemic Antibiotic Therapy for Generalized Aggressive Periodontitis

2007 ◽  
Vol 78 (7) ◽  
pp. 1201-1208 ◽  
Author(s):  
Doğan Kaner ◽  
Claudia Christan ◽  
Thomas Dietrich ◽  
Jean-Pierre Bernimoulin ◽  
Bernd-Michael Kleber ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Antibiotic Therapy ◽  
Aggressive Periodontitis ◽  
Systemic Antibiotic ◽  
Systemic Antibiotic Therapy

Current antibiotic therapy of endo-perio lesions with secondary endodontic involvement

2021 ◽  
Vol 26 (2) ◽  
pp. 105-113
Author(s):  
L. Yu. Orekhova ◽  
V. G. Atrushkevitch ◽  
E. S. Loboda ◽  
V. Yu. Vashneva ◽  
A. A. Petrov
Keyword(s):  
Antibiotic Therapy ◽  
Antibiotic Sensitivity ◽  
Endodontic Treatment ◽  
Comprehensive Treatment ◽  
Sensitivity Testing ◽  
Microbiological Test ◽  
Systemic Antibiotic ◽  
Periodontal Inflammation ◽  
Systemic Antibiotic Therapy ◽  
Group 2

Relevance. Successful treatment of endo-perio lesions depends on the thorough clinical assessment, accurate diagnosis and structural approach to the planning of periodontal and endodontic treatment. Aim – to provide clinical and laboratory evidence about the effectiveness of ciprofloxacin-and-tinidazole-containing antibiotic in the comprehensive treatment of endo-perio lesions with a primary periodontal disease which secondarily affects the pulp.Materials and methods. We examined 29 patients aged from 35 to 50 (mean age 42.3±3.21) with class II endo-perio lesions according to P. Eickholz classification. The patients were randomly divided into 2 groups. All patients had comprehensive periodontal and endodontic treatment with (Group 2) and without (Group 1) antibiotic therapy. The clinical and paraclinical examination included determination of such indices as OHI-s, SL, PMA, SBI, as well as Doppler ultrasound, EPT, CBCT, microbiological test of the discharge from periodontal pockets and root canal system. We selected the systemic antibiotic after the antibiotic sensitivity testing.Results. Comprehensive treatment of endo-perio lesions, which included systemic antibiotic therapy with ciprofloxacin and tinidazole, effectively arrested the inflammation in the periodontium and pulp beginning from the 7th day of use.Conclusion. Cifran ST, a combination broad-spectrum antibiotic, helps reduce periodontal inflammation by effectively eliminating microbiota in the root canals and periodontal pockets in patients with moderate or severe chronic generalized periodontitis. 

scholarly journals Use of Staphylococcus aureus Phage Lysate Staphage Lysate (SPL)® for the Control of Recurrent Pyoderma Eczema in Dogs with Atopic Dermatitis

2018 ◽  
Vol 44 (1) ◽  
pp. 7 ◽  
Author(s):  
Suzana Evelyn Bahr Solomon ◽  
Marconi Rodrigues de Farias ◽  
Claudia Turra Pimpão
Keyword(s):  
Staphylococcus Aureus ◽  
Atopic Dermatitis ◽  
Antibiotic Therapy ◽  
Significant Decline ◽  
Microbiological Analysis ◽  
Phage Lysate ◽  
Systemic Antibiotic ◽  
Therapeutic Protocol ◽  
Systemic Antibiotic Therapy ◽  
The Mean

Background: Recurrent staphylococcal infections are frequent in dogs with atopic dermatitis (AD). Many factors seem to contribute to making bacterial pyoderma refractory to treatment. Short-term systemic antibiotic therapy is effective for the treatment of acute symptoms, and may, along with pulsatile therapy, contribute to the long-term control of the disease. However, microbial resistance has become a growing and alarming problem. The aim of this study was to evaluate whether the use of Staphylococcus aureus Phage Lysate Staphage Lysate (SPL)®, can minimize the symptoms of recurrent pyoderma and increase the interval between acute atopic manifestations in dogs.Materials, Methods & Results: Thirteen dogs with a history of Canine Atopic Dematitis (CAD) and recurrent bacterial pyoderma received SPL at increasing intervals for 23 weeks. The contents of an intact pustule of each dog was collected and submitted to microbiological analysis. Systemic antibiotic therapy was established for the first 4-6 weeks of SPL protocol, based on the antibiotic sensitivity tests. The animals included in the study underwent a therapeutic protocol receiving shots of 0.5 mL of SPL subcutaneously (SC) twice a week for the first 12 weeks; 1.0 mL of SPL (SC) once a week for four weeks; 1.0 mL of SPL (SC) once every 15 days; 1.0 mL of SPL (SC) after a three-week interval from the last dose on week 20, until final observation at week 26, with no application. The animals underwent clinical examination every week and the evaluation of pruritus was used according Rybnicek et al. During the therapeutic protocol with SPL, a significant decline in the pruritus was observed in the treated dogs (P < 0.05). In week 1, the mean pruritus index was 7.33 on the Rybnicek scale; in weeks 12 and 23, the mean indices were 2.41 and 1.91. An effectiveness of 83.33% for the control of pruritus along with regression of the lesions was observed.Discussion: Before treatment, the selected animals presented worsening of the pruritus during the pyoderma eczema episodes (pruritic), resulting in the emergence of a vicious cycle where the pruritus induced the appearance of new lesions, requiring the use of antibiotics for a long period. During the therapeutic protocol with SPL, a significant decline in the pruritus was observed in the treated dogs. The control of pruritus associated with pyoderma eczema of the dogs in this study before the vaccination protocol with SPL was satisfactory when they were subjected to antibiotic therapy; however, after suspending therapy, the bacterial infections recurred, on average, after 2-4 weeks. On the other hand, with the use of SPL, the animals were recurrence-free until the end of the experimental protocol. This was attributed to the antibiotic therapy administered at the beginning of the protocol, as this led to a regression of the bacterial pyoderma and involution of the lesions. However, after suspending antibiotics, it was observed that, by the end of the study, 83.33% of the dogs still had a low level of pruritus, few or no lesions, which were considered acceptable to most owners. At this moment none of these patients needed to be subjected to antibiotic treatment. The sums of the scores for the dogs on weeks 1, 12, and 23 were 53.33, 4.41, and 3.5, respectively, indicating significant improvements of the lesions, showing that the proposed protocol with SPL was able to prevent new episodes of pyoderma.

scholarly journals Non-infectious causes of chronic pharyngitis

2018 ◽  
pp. 112-115
Author(s):  
S. Ya. Kosyakov ◽  
I. B. Angotoeva ◽  
A. N. Isamov
Keyword(s):  
Antibiotic Therapy ◽  
Sore Throat ◽  
Inflammatory Process ◽  
Common Disease ◽  
Main Symptom ◽  
Systemic Antibiotic ◽  
Pharyngeal Mucosa ◽  
Systemic Antibiotic Therapy

Chronic pharyngitis (CP) is a common disease that is not associated with infections and does not require administration of any systemic antibiotic therapy. Many non-infectious factors cause CP. Despite diversity and variability of factors, the inflammatory process of the pharyngeal mucosa lie at the root of the pathogenesis of CP. A sore throat is the main symptom of this process, which can be successfully relieved with local drugs.

Sign in / Sign up

Export Citation Format

Share Document